Home page4507 • TYO
add
Shionogi & Co.
Chiusura precedente
2366,50Â ÂĄ
Intervallo giornaliero
2376,50Â ÂĄ - 2418,00Â ÂĄ
Intervallo annuale
1944,66Â ÂĄ - 2550,00Â ÂĄ
Cap di mercato
2,14Â Bln JPY
Volume medio
2,68Â Mln
Rapporto P/E
12,15
Dividendo/Prezzo
2,36%
Borsa valori principale
TYO
Notizie
4551
0,16%
0,22%
Dati finanziari
Conto economico
Entrate
Utile netto
(JPY) | dic 2024info | Variazione Y/Y |
---|---|---|
Entrate | 119,63Â Mld | 12,56% |
Spese di gestione | 50,38Â Mld | -1,47% |
Utile netto | 50,67Â Mld | 38,33% |
Margine di profitto netto | 42,36 | 22,89% |
Utili per azione | — | — |
EBITDA | 58,79Â Mld | 30,07% |
Aliquota fiscale effettiva | 18,66% | — |
Stato patrimoniale
Totale attivo
Totale passivo
(JPY) | dic 2024info | Variazione Y/Y |
---|---|---|
Investimenti cash/breve termine | 305,58Â Mld | 7,30% |
Totale attivo | 1,52Â Bln | 11,52% |
Totale passivo | 153,98Â Mld | 5,81% |
Patrimonio netto totale | 1,36 Bln | — |
Azioni in circolazione | 850,69 Mln | — |
Prezzo/valore contabile | 1,50 | — |
Redditività dell'attivo | 8,97% | — |
Rendimento sul capitale | 9,85% | — |
Flusso di cassa
Flusso di cassa netto
(JPY) | dic 2024info | Variazione Y/Y |
---|---|---|
Utile netto | 50,67Â Mld | 38,33% |
LiquiditĂ di esercizio | 40,80Â Mld | 89,55% |
Contanti da investimenti | -17,23Â Mld | -129,68% |
Contanti da finanziamenti | -24,92Â Mld | 50,49% |
Flusso di cassa netto | 2,17Â Mld | -93,30% |
Flusso di cassa libero | -36,12Â Mln | -100,05% |
Informazioni
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m. Wikipedia
Fondazione
5 giu 1919
Sito web
Dipendenti
4.959